Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 72.44%, Green Power Environmental (01330) at 69.47%, and Da Zhong Public Utilities (01635) at 69.41% [1][2] - Alibaba-W (09988), Tracker Fund of Hong Kong (02800), and Xiaomi Group-W (01810) saw the largest increases in holding amounts over the last five trading days, with increases of +6.391 billion, +5.358 billion, and +2.533 billion respectively [1][2] - WuXi Biologics (02269), China Mobile (00941), and Crystal International (02228) experienced the largest decreases in holding amounts, with reductions of -612 million, -485 million, and -473 million respectively [1][3] Hong Kong Stock Connect Holding Ratios - China Telecom (00728) holds 10.054 billion shares, representing 72.44% of its total [2] - Green Power Environmental (01330) holds 281 million shares, representing 69.47% of its total [2] - Da Zhong Public Utilities (01635) holds 370 million shares, representing 69.41% of its total [2] Recent Increases in Holdings - Alibaba-W (09988) saw an increase of +6.391 billion in holding amount, with a change of +41.368 million shares [2] - Tracker Fund of Hong Kong (02800) increased by +5.358 billion, with a change of +207.532 million shares [2] - Xiaomi Group-W (01810) increased by +2.533 billion, with a change of +65.508 million shares [2] Recent Decreases in Holdings - WuXi Biologics (02269) decreased by -612 million in holding amount, with a change of -19.247 million shares [3] - China Mobile (00941) decreased by -485 million, with a change of -5.542 million shares [3] - Crystal International (02228) decreased by -473 million, with a change of -46.770 million shares [3]

Group 1 - Morgan Stanley's research report indicates that WuXi AppTec's valuation levels are attractive amid a stable fundamental backdrop, with a particular focus on WuXi Biologics [1] - The report highlights that WuXi Biologics has raised its earnings guidance and is undergoing significant capacity expansion, with high participation in the next-generation GLP-1 sector [1] - The firm has upgraded earnings forecasts for WuXi Biologics for 2025 to 2027 by 6% to 13%, and for WuXi AppTec by 3% to 4%, designating WuXi AppTec as a top pick [1] Group 2 - The compound annual growth rates for the three companies from 2024 to 2027 are projected at 24%, 23%, and 37% respectively [1] - Other major banks, including Oriental Securities and Goldman Sachs, have also maintained positive ratings on WuXi AppTec and WuXi Biologics, citing strong performance and robust customer demand [2] - Goldman Sachs set a target price of HKD 63.3 for WuXi AppTec, reflecting confidence in the company's order momentum and customer demand [2]

Group 1 - CRO concept stocks have collectively rebounded, indicating a positive trend in the sector [1] - Tigermed (03347.HK) increased by 9.19%, reaching HKD 39.92 [1] - WuXi AppTec (02359.HK) rose by 4.43%, trading at HKD 106 [1] - Kanglong Chemical (03759.HK) saw a 4.15% increase, priced at HKD 21.58 [1] - WuXi Biologics (02269.HK) experienced a 3.27% rise, with a price of HKD 31.56 [1]

Core Insights - The Hong Kong stock market indices saw significant gains in the afternoon, with the Hang Seng Index rising over 2%, the Hang Seng Tech Index increasing by 2.7%, and the Hang Seng China Enterprises Index up by 1.8% [1] Company Performance - Kuaishou (快手-W) experienced a rise of 6.56% with a year-to-date increase of 66.79%, and a total market capitalization of 294.57 billion [2] - NetEase (网易-S) increased by 6.26%, with a year-to-date gain of 61.57%, and a market cap of 688.29 billion [2] - Alibaba (阿里巴巴-W) rose by 5.42%, showing a year-to-date increase of 93.41%, with a total market value of 2.97 trillion [2] - WuXi AppTec (药明康德) saw a 4.14% increase, with a year-to-date rise of 93.30%, and a market capitalization of 315.38 billion [2] - Baidu (百度集团-SW) increased by 4.10%, with a year-to-date gain of 35.07%, and a market cap of 307.19 billion [2] - Hansoh Pharmaceutical (翰森制药) rose by 4.03%, with a remarkable year-to-date increase of 134.85%, and a market capitalization of 240.51 billion [2] - Zhongsheng Holdings (中升控股) increased by 3.58%, but has a year-to-date decline of 12.81%, with a market cap of 27.41 billion [2] - China Overseas Development (中国海外发展) rose by 3.37%, with a year-to-date increase of 19.16%, and a market cap of 154.54 billion [2] - Longfor Group (龙湖集团) increased by 3.54%, with a year-to-date rise of 6.20%, and a market cap of 72.18 billion [2] - BYD (比亚迪股份) rose by 3.34%, with a year-to-date increase of 9.64%, and a market cap of 873.88 billion [2] - WuXi Biologics (药明生物) increased by 3.34%, with a year-to-date rise of 79.84%, and a market cap of 129.71 billion [2] - Midea Group (美的集团) rose by 2.92%, with a year-to-date increase of 26.14%, and a market cap of 690.12 billion [2] - Meituan (美团-W) increased by 2.88%, but has a year-to-date decline of 35.20%, with a market cap of 600.76 billion [2] - Alibaba Health (阿里健康) rose by 2.87%, with a year-to-date increase of 72.59%, and a market cap of 92.68 billion [2]

Group 1 - The CRO sector is experiencing a collective rebound, with notable stock price increases for companies such as Tigermed (up 9.19% to HKD 39.92), WuXi AppTec (up 4.43% to HKD 106), and others [1] - Citing a recovery in capital market financing activities and an expansion in the overseas trading scale of innovative drugs, the outlook for CXO companies' performance in the second half of the year is optimistic [1] - Morgan Stanley notes that since mid-September, healthcare stocks have been under pressure as investors take profits, but the fundamentals for WuXi's companies remain strong, making their valuations more attractive [1] Group 2 - WuXi AppTec is highlighted as a top pick due to its raised earnings guidance and significant capacity expansion, particularly in the next-generation GLP-1 sector [1] - The projected compound annual growth rates for WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiary from 2024 to 2027 are 24%, 23%, and 37% respectively [1]

Group 1 - CRO concept stocks have collectively rebounded, with notable increases in share prices: Tigermed (300347) up 9.19% to HKD 39.92, WuXi AppTec (603259) up 4.43% to HKD 106, and others showing similar gains [1] - CMB International believes that the recovery of capital market financing activities, expansion of overseas transactions for innovative drugs, and a rebound in domestic R&D demand will lead to a recovery in CXO companies' performance in the second half of the year [1] - Morgan Stanley reports that healthcare stocks have been sold off since mid-September, with investors taking profits while awaiting signals for next year's performance [1] Group 2 - Morgan Stanley highlights that WuXi AppTec's fundamentals remain strong, making its valuation more attractive, especially as the company has raised its earnings guidance and is expanding capacity significantly [1] - The projected compound annual growth rates for earnings from WuXi AppTec, WuXi Biologics, and WuXi AppTec's subsidiaries from 2024 to 2027 are 24%, 23%, and 37% respectively [1]

Summary of WuXi Biologics Conference Call Company Overview - **Company**: WuXi Biologics (2269.HK) - **Event**: APAC Healthcare Corporate Day 2025 - **Date**: November 20, 2025 Key Industry Insights - **New Order Momentum**: Management indicated that new order momentum remains robust as the company heads into Q4 2025, with expectations for accelerated revenue and earnings growth in 2026 [2][3] - **R&D Projects**: A rebound in R&D projects was noted, driven by global funding recovery and increased PPQ scheduling. Bi-/multi-specific antibodies and ADCs are identified as key growth drivers, with respective project increases of +36.6% y/y to 168 projects and +34.7% y/y to 225 projects, together accounting for 71% of new projects as of 1H25 [3][2] Financial Performance and Projections - **Revenue Guidance**: Management plans to provide further clarity on revenue and project guidance at an industry conference in early 2026, with detailed updates expected during the full-year earnings release in March 2026 [2] - **Capex Plan**: The annual capital expenditure (capex) budget is projected to exceed RMB 5 billion through 2027, focusing on overseas expansion. Long-term capacity is targeted to reach 500kL, with 50% of this capacity located in China [4][7] Operational Efficiency - **Margin Management**: The margin dilution from the Singapore site is considered manageable due to favorable tax policies and operational efficiencies. Utilization rates at domestic sites have improved from 60% to 65% and are expected to continue rising [8][2] - **Project Updates**: A project at the Shijiazhuang site has received Breakthrough Therapy Designation (BTD) and is targeted for Biologics License Application (BLA) filing by year-end, which could significantly enhance utilization post-launch [8] Risks and Price Target - **Price Target**: The 12-month price target is set at HK$33.50, based on a forward P/E of 26x, indicating a potential upside of 4.9% from the current price of HK$31.92 [10] - **Risks**: Key risks include potential legislative impacts on US revenue, cooling of global biotech funding, and increasing competition from global players [9][10] Conclusion WuXi Biologics is positioned for growth with strong order momentum and strategic expansion plans. The focus on R&D and operational efficiency, alongside a robust capex plan, supports the company's outlook for 2026. However, investors should remain cautious of external risks that could impact performance.

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 72.38%, Green Power Environmental (01330) at 69.48%, and Da Zhong Public Utilities (01635) at 69.45% [1][2] - Alibaba-W (09988), Xiaomi Group-W (01810), and the Tracker Fund of Hong Kong (02800) saw the largest increases in holding amounts over the last five trading days, with increases of +70.62 billion, +33.67 billion, and +15.78 billion respectively [1][2] - WuXi Biologics (02269), China Shenhua (01088), and China Mobile (00941) experienced the largest decreases in holding amounts over the same period, with decreases of -6.43 billion, -3.93 billion, and -3.75 billion respectively [1][3] Group 1: Hong Kong Stock Connect Holding Ratios - China Telecom (00728) has a holding of 100.45 billion shares, representing 72.38% [2] - Green Power Environmental (01330) has a holding of 2.81 billion shares, representing 69.48% [2] - Da Zhong Public Utilities (01635) has a holding of 3.71 billion shares, representing 69.45% [2] Group 2: Recent Increases in Holdings - Alibaba-W (09988) saw an increase of +70.62 billion in holding amount, with a change of +47.84 million shares [2] - Xiaomi Group-W (01810) experienced an increase of +33.67 billion, with a change of +88.41 million shares [2] - The Tracker Fund of Hong Kong (02800) had an increase of +15.78 billion, with a change of +62.24 million shares [2] Group 3: Recent Decreases in Holdings - WuXi Biologics (02269) had a decrease of -6.43 billion in holding amount, with a change of -21.06 million shares [3] - China Shenhua (01088) saw a decrease of -3.93 billion, with a change of -9.94 million shares [3] - China Mobile (00941) experienced a decrease of -3.75 billion, with a change of -4.36 million shares [3]

Core Viewpoint - The CXO sector in the A-share market is experiencing significant growth, with 20 out of 29 listed companies reporting year-on-year revenue increases in the first three quarters, driven by internationalization and policy support for innovative drug companies [1][2]. Group 1: Industry Trends - Three major trends are emerging in the innovative drug sector: 1. Deepening internationalization 2.0, with an expected 103 license-out transactions and a record upfront payment of $8.45 billion by 2025, leading to valuation premiums for companies going abroad [2]. 2. Unprecedented policy support, including improved efficiency in medical insurance negotiations and the establishment of a commercial insurance directory for innovative drugs [2]. 3. Continuous technological breakthroughs, with advancements in ADC, IO dual antibodies, GLP-1 weight loss drugs, and small nucleic acid drugs [2]. Group 2: Market Outlook - The CXO industry adjustment is largely complete, with stable overseas demand and a rebound in domestic investment and financing, particularly for CDMO companies with strong international capabilities and leading clinical CROs [2]. - The recovery of the upstream industry chain is significant, with ample room for increasing domestic production rates, driven by smart and digital production alongside international expansion [2]. - The capital market's recovery in financing activities and the expansion of innovative drug transactions abroad, combined with a potential recovery in domestic innovative drug R&D demand, are expected to boost CXO companies' performance in the second half of the year [1]. Group 3: Key Companies - Leading companies in the CXO sector include: - Kelaiying (06821) - Kanglong Chemical (03759) - Zhaoyan New Drug (06127) - WuXi Biologics (02269) - WuXi AppTec (02359) [3].

Group 1 - Recent focus on the unlocking of restricted shares in the Hong Kong stock market, with significant declines observed in stock prices, such as a drop of 8.75% for CATL's H-shares [1] - Upcoming unlocks for companies including Sanhua Intelligent Control and Hengrui Medicine, with Hai Tian Flavor Industry scheduled for December, potentially exerting pressure on stock prices [1] - The Hang Seng Technology Index has experienced a correction of over 18% since its peak after the National Day holiday, indicating a broader market trend [1] Group 2 - Continuous inflow of funds into the Hang Seng Technology/ Hong Kong Technology/ Hong Kong Stock Connect Internet sectors, with the Hong Kong Technology ETF (159751) seeing a net inflow of 50.63 million yuan over four days [1] - The average daily net inflow for the Hong Kong Technology ETF reached 12.66 million yuan, highlighting investor interest [1] - Institutional investors are expected to have reduced pressure for profit-taking in November and December, leading to a neutral upward expectation for the index despite economic meeting forecasts [1] Group 3 - The CSI Hong Kong Stock Connect Technology Index (931573) includes top-weighted stocks such as Alibaba, Tencent, and SMIC, with the top ten stocks accounting for 66.81% of the index [2]